Tokyo Tape
Sign in
← PeptiDream

Half-year report · Q2

4587.TEDINET S100U7ET
Period2024-01-01 → 2024-06-30
Filed2024-08-09
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥36.1bn2024-01-01 → 2024-06-30Cons.Revenue IFRS
Revenue¥28.7bn2023-01-01 → 2023-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥9.4bn2023-01-01 → 2023-06-30Cons.Revenue IFRS
Operating income¥24.6bn2024-01-01 → 2024-06-30Cons.Operating profit loss IFRS
Operating income−¥986m2023-01-01 → 2023-06-30Cons.Operating profit loss IFRS
Profit before tax¥24.7bn2024-01-01 → 2024-06-30Cons.Profit loss before tax IFRS
Profit before tax¥4.4bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥1.1bn2023-01-01 → 2023-06-30Cons.Profit loss before tax IFRS
Net income (owners)¥17.9bn2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥3.0bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥729m2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥17.9bn2024-01-01 → 2024-06-30Cons.Profit loss IFRS
Net income¥3.0bn2023-01-01 → 2023-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥729m2023-01-01 → 2023-06-30Cons.Profit loss IFRS
Total assets¥95.9bnat 2024-06-30Cons.Assets IFRS
Total assets¥69.5bnat 2023-12-31Cons.Assets IFRS
Total assets¥57.7bnat 2023-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥37.1bnat 2024-06-30Cons.Liabilities IFRS
Total liabilities¥29.1bnat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥58.8bnat 2024-06-30Cons.Equity IFRS
Net assets / equity¥40.3bnat 2023-12-31Cons.Equity IFRS
Net assets / equity¥31.0bnat 2023-06-30Cons.Equity IFRS
Net assets / equity¥32.0bnat 2022-12-31dCons.Equity IFRS
Equity (owners)¥58.8bnat 2024-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥40.3bnat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥31.0bnat 2023-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥25.5bnat 2024-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥19.5bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.2bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥5.2bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥2.7bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥12.4bn2023-01-01 → 2023-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥8.8bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow¥10.0bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow¥1.3bn2023-01-01 → 2023-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥798m2023-01-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥1.5bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥264m2023-01-01 → 2023-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥2.3bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥138.32024-01-01 → 2024-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥23.412023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-5.622023-01-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥138.112024-01-01 → 2024-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥23.382023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-5.622023-01-01 → 2023-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio61.3%at 2024-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio58.1%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio53.8%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-06-30−¥178m
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-06-30−¥178m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥28.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥28.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2024-01-01 → 2024-06-30¥24.7bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥7.8bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥7.7bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2024-01-01 → 2024-06-30¥178m
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥47m
—segment totalrevenue2024-01-01 → 2024-06-30¥36.3bn
—segment totalrevenue external2024-01-01 → 2024-06-30¥36.1bn
—segment totalrevenue intersegment2024-01-01 → 2024-06-30¥178m
—segment totalsegment profit2024-01-01 → 2024-06-30¥24.7bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-06-30−¥30m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-06-30−¥30m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥1.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥1.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2023-01-01 → 2023-06-30−¥1.2bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥8.0bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥8.0bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥30m
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-06-30¥228m
—segment totalrevenue2023-01-01 → 2023-06-30¥9.5bn
—segment totalrevenue external2023-01-01 → 2023-06-30¥9.4bn
—segment totalrevenue intersegment2023-01-01 → 2023-06-30¥30m
—segment totalsegment profit2023-01-01 → 2023-06-30−¥941m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 586
ItemContextValueUnit
Equity IFRSCurrentQuarterInstant_ShareCapitalIFRSMember3956738000JPY
Equity IFRSCurrentQuarterInstant_CapitalSurplusIFRSMember4566129000JPY
Equity IFRSCurrentQuarterInstant_TreasurySharesIFRSMember-1075128000JPY
Equity IFRSCurrentQuarterInstant_RetainedEarningsIFRSMember52269245000JPY
Equity IFRSCurrentQuarterInstant_OtherComponentsOfEquityIFRSMember-946349000JPY
Equity IFRSCurrentQuarterInstant_EquityAttributableToOwnersOfParentIFRSMember58770634000JPY
Equity IFRSCurrentQuarterInstant58770634000JPY
Profit loss before tax IFRSPrior1YTDDuration-1110932000JPY
Profit loss before tax IFRSCurrentYTDDuration24742228000JPY
Depreciation and amortization ope cf IFRSPrior1YTDDuration1221011000JPY
Depreciation and amortization ope cf IFRSCurrentYTDDuration1154343000JPY
Interest and dividend income ope cf IFRSPrior1YTDDuration-5792000JPY
Interest and dividend income ope cf IFRSCurrentYTDDuration-481000JPY
Interest expenses ope cf IFRSPrior1YTDDuration116872000JPY
Interest expenses ope cf IFRSCurrentYTDDuration136342000JPY
Foreign exchange loss gain ope cf IFRSPrior1YTDDuration-270895000JPY
Foreign exchange loss gain ope cf IFRSCurrentYTDDuration-128293000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSPrior1YTDDuration103231000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSCurrentYTDDuration105927000JPY
Decrease increase in trade and other receivables ope cf IFRSPrior1YTDDuration12060426000JPY
Decrease increase in trade and other receivables ope cf IFRSCurrentYTDDuration-27795103000JPY
Decrease increase in inventories ope cf IFRSPrior1YTDDuration33568000JPY
Decrease increase in inventories ope cf IFRSCurrentYTDDuration-385782000JPY
Increase decrease in trade and other payables ope cf IFRSPrior1YTDDuration-1186090000JPY
Increase decrease in trade and other payables ope cf IFRSCurrentYTDDuration436504000JPY
Increase or decrease in retirement benefit asset or liability ope cf IFRSPrior1YTDDuration2175000JPY
Increase or decrease in retirement benefit asset or liability ope cf IFRSCurrentYTDDuration-4813000JPY
Other changes in working capital ope cf IFRSPrior1YTDDuration208303000JPY
Other changes in working capital ope cf IFRSCurrentYTDDuration178365000JPY
Subtotal ope cf IFRSPrior1YTDDuration11171878000JPY
Subtotal ope cf IFRSCurrentYTDDuration-1560762000JPY
Interest and dividends received ope cf IFRSPrior1YTDDuration5792000JPY
Interest and dividends received ope cf IFRSCurrentYTDDuration481000JPY
Interest paid ope cf IFRSPrior1YTDDuration-91717000JPY
Interest paid ope cf IFRSCurrentYTDDuration-108802000JPY
Income taxes paid ope cf IFRSPrior1YTDDuration-2316431000JPY
Income taxes paid ope cf IFRSCurrentYTDDuration-1015740000JPY
Income taxes refund ope cf IFRSPrior1YTDDuration－JPY
Income taxes refund ope cf IFRSCurrentYTDDuration24912000JPY
Net cash provided by used in operating activities IFRSPrior1YTDDuration8769521000JPY
Net cash provided by used in operating activities IFRSCurrentYTDDuration-2659911000JPY
Proceeds from sale of investment securities inv cf IFRSPrior1YTDDuration－JPY
Proceeds from sale of investment securities inv cf IFRSCurrentYTDDuration10935460000JPY
Purchase of investment securities inv cf IFRSPrior1YTDDuration-200000000JPY
Purchase of investment securities inv cf IFRSCurrentYTDDuration－JPY
Collection of loans receivable inv cf IFRSPrior1YTDDuration3121000JPY
Collection of loans receivable inv cf IFRSCurrentYTDDuration3122000JPY
Purchase of property plant and equipment inv cf IFRSPrior1YTDDuration-547145000JPY
Purchase of property plant and equipment inv cf IFRSCurrentYTDDuration-928858000JPY
Purchase of intangible assets inv cf IFRSPrior1YTDDuration-53632000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass rounding
balance sheet identityconsolidated 2024-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-06-30pass